Dean McKinney, Catalent’s Vice President of Pulmonary and Nasal Development, states “We have a strong history in inhalation built around our talented team of scientists, who have experience gained from supporting numerous inhaled products and dosage forms available on the market today. It is this talent and experience we hope to share with the industry at large for the advancement of patient treatments through active participation in IPAC-RS.”
Jackie Schumacher, IPAC-RS Chair, and CMC Portfolio Director - Established Products/Emerging Markets, Pfizer, commented, "We are delighted to welcome Catalent into the Consortium. Catalent's work in the orally inhaled and nasal drug field, combined with its interest in contributing constructively to IPAC-RS' strategic initiatives, will be an asset to the Consortium. Catalent shares IPAC-RS' goal of advancing consensus-based, scientifically driven standards and regulations for orally inhaled and nasal drug products, and facilitating the availability of high-quality, safe, and efficacious drug products to patients. Catalent's decision to join IPAC-RS also highlights the recent strategic Consortium goal of encouraging a broader and diverse number of companies that develop, manufacture or market orally inhaled and nasal drug products to join IPAC-RS. This engagement occurs at a time when the Consortium is expanding the scope of its initiatives beyond developed markets and focusing on advances in emerging markets.”
In this new membership, Catalent joins leading pulmonary and nasal drug innovators including 3M, AstraZenaca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mannkind Corporation, Merck & Co, Novartis, Pfizer, Teva, Vectura Ltd and others who have made IPAC-RS the leading resource and advocate of OINDP industry. McKinney says “Catalent looks forward to this opportunity to assist in shaping the business and regulatory environment through collaborative workshops, expert roundtables, training classes and working groups aimed at tackling technical issues.”
About Catalent
From drug and biologic development services to delivery technologies to supply solutions, Catalent Pharma Solutions has the deepest expertise, the broadest offerings and the most unique technologies in the industry. With over 75 years of experience, Catalent helps customers get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging solutions. Catalent employs more than 8,000 people at 20+ facilities worldwide and in fiscal year 2011 generated more than $1.6 billion in annual revenue. Catalent is headquartered in Somerset, NJ. For more information, visit www.catalent.com.
more products. better treatments. reliably supplied.™
Media Contact: Patricia McGee
T +1(732) 537 6407 | F (732) 357 6490
patricia.mcgee@catalent.com
